News
Novartis UK awarded Innovation Passport for investigational therapy
Novartis have announced that the investigational oral therapy, iptacopan (LNP023), has been awarded an Innovation Passport for the treatment of C3 glomerulopathy (C3G) by the MHRA, NICE, and the SMC.